Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188469 | 0.94 | SMN1; SMN2 (0.44) | L3MBTL1TDP1POLBSMN1; SMN2MAPT | |
| SCHEMBL17048233 | 0.86 | HTT (0.42) | L3MBTL1POLBSMN1; SMN2MAPTRAB9A | |
| SCHEMBL27733869 | 0.86 | TDP1 (0.59) | L3MBTL1TDP1PTGS2CYP3A4GPR84 | |
| Hydrochloric Acid SCHEMBL28015977 | 0.84 | TDP1 (0.57) | L3MBTL1TDP1PTGS2CYP3A4SMN1; SMN2 | |
| SCHEMBL27563659 | 0.84 | TDP1 (0.57) | L3MBTL1TDP1PTGS2CYP3A4SMN1; SMN2 | |
| SCHEMBL1419853 | 0.81 | HRH1 (0.49) | — | |
| SCHEMBL28307287 | 0.79 | TDP1 (0.49) | L3MBTL1TDP1PTGS2CYP3A4GPR84 | |
| SCHEMBL10807925 | 0.79 | TDP1 (0.50) | L3MBTL1TDP1PTGS2CYP3A4POLB | |
| SCHEMBL19909213 | 0.78 | TDP1 (0.52) | L3MBTL1TDP1PTGS2CYP3A4POLB | |
| SCHEMBL197194 | 0.78 | TDP1 (0.52) | L3MBTL1TDP1PTGS2CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305883-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-10-26 | — | — | US | disclosed |
| US-20170190705-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-06 | — | — | US | disclosed |
| EP-3122355-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | The Brigham and Women's Hospital, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148654-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-7101896-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-7022706-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | DULL GARY M | 2005-12-01 | — | — | US | disclosed |
| US-6890935-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040152723-A1 | Pharmaceutical compositions and methods for use | CLARK THOMAS JEFFREY (US) | 2004-08-05 | — | — | US | disclosed |
| US-6624167-B1 | Compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can | TARGACEPT, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-1305316-A2 | AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | Targacept, Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-0984966-B1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH AS (DK) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002088114-A2 | HETEROARYL OFEFINIC AZACYCLIC AND HETEROARYL ACETYLENIC AZACYCLIC COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | TARGACEPT, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002004442-A9 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT INC (US) | 2002-06-13 | — | — | WO | disclosed |
| US-6392045-B1 | 9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors | NEUROSEARCH A/S (DK) | 2002-05-21 | — | — | US | disclosed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2002012245-A2 | AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | TARGACEPT, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002004442-A2 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-0984966-A1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH A/S (DK) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054182-A1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH A/S (DK) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | L3MBTL1 4882/4885TDP1 2098/4885PTGS2 853/4885 |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | L3MBTL1 4882/4885TDP1 2098/4885PTGS2 853/4885 |
| US-20170305883-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | L3MBTL1 1095/4885TDP1 4297/4885PTGS2 1700/4885 |
| US-20040152723-A1 | Pharmaceutical compositions and methods for use | CHRNA7, CHRNA10, CHRNG | L3MBTL1 4828/4885TDP1 867/4885PTGS2 3163/4885 |
| US-20170190705-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | L3MBTL1 1117/4885TDP1 4274/4885PTGS2 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.